Fax: (215) 627-3925
Adjuvant therapy in stage I carcinoma of the breast†
The influence of multigene analyses and molecular phenotyping
Article first published online: 5 MAR 2012
Copyright © 2012 American Cancer Society
Volume 118, Issue 8, pages 2031–2038, 15 April 2012
How to Cite
Schwartz, G. F., Reis-Fihlo, J., Pusztai, L., Fentiman, I. S., Holland, R., Bartelink, H., Rutgers, E. J. T., Solin, L. J., Palazzo, J. and and the Consensus Committee (2012), Adjuvant therapy in stage I carcinoma of the breast. Cancer, 118: 2031–2038. doi: 10.1002/cncr.27431
The following participated in the 2010 Breast Health International Breast Cancer Consensus Conference, Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses And Molecular Phenotyping, held October 24-26, 2010 in Philadelphia, Pennsylvania: Gordon F. Schwartz, MD, MBA (Jefferson Medical College, Philadelphia, Pa); Harry Bartelink, MD, PhD (The Netherlands Cancer Institute, Amsterdam, the Netherlands); Harold J. Burstein, MD, PhD (Harvard Medical School, Dana-Farber Cancer Institute, Boston, Mass); Blake Cady, MD (Harvard Medical School, Boston, MA);Luigi Cataliotti, MD (University of Florence, Florence, Italy); Ian S. Fentiman, MD (Guys Hospital, London, United Kingdom); Roland Holland, MD (University Hospital Nijmegen, Nigmegen, the Netherlands); Kevin S. Hughes, MD (Harvard Medical School, Massachusetts General Hospital, Boston, MA); Shahla Masood, MD (University of Florida Health Science Center, Jacksonville, Fla); Beryl McCormick, MD (Memorial Sloan-Kettering Cancer Center, New York, NY); Juan A. Palazzo, MD (Jefferson Medical College, Philadelphia, Pa); Peter I. Pressman, MD (New York-Presbyterian Hospital, New York, NY); Jorge Reis-Filho, MD (Chester Beatty Laboratories, London, United Kingdom); Lajos Pusztai, MD (The University of Texas M. D. Anderson Cancer Center, Houston, Tex); Emiel J. T. Rutgers, MD (Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands); Andrew D. Seidman, MD (Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY); Lawrence J. Solin, MD, (Albert Einstein Medical Center, Philadelphia, Pa); and Joseph A. Sparano, MD (Albert Einstein College of Medicine, Bronx, NY).
- Issue published online: 6 APR 2012
- Article first published online: 5 MAR 2012
- Manuscript Accepted: 6 DEC 2011
- Manuscript Revised: 27 NOV 2011
- Manuscript Received: 4 SEP 2011
- hormone receptors;
- gene expression;
- breast cancer
Breast Health International and the Kimmel Cancer Center of Thomas Jefferson University cosponsored a consensus conference that included an international group of experts.
Since the adoption of adjuvant chemotherapy for stage I, lymph node-negative breast cancers in 1988, investigators have tried to “fine-tune” the treatment criteria. At this consensus conference, the group debated recommendations for adjuvant hormone and cytotoxic chemotherapy in stage I breast cancers.
Discussions during the conference addressed issues of adjuvant therapy for stage I breast cancer and the influence of multigene analyses and molecular phenotyping. The panelists discussed various demographic, morphologic, biologic, and genetic factors expressed by individual tumors and their influence on treatment decisions.
The panel tried to create guidelines for the consideration of adjuvant treatment of these patients, including both hormone and cytotoxic regimens. They also encouraged further research into the molecular analysis of breast cancers and the introduction of clinical trials based on current data, although they concluded that it is too early to add any of those analyses into the decision-making algorithms of recommendations for the treatment of stage I breast cancer. Cancer 2012;. © 2012 American Cancer Society.